Drug intelligence / Profile preview

BIL-1

Development stage: Unknown
Lead developer: Shanghai Skin Disease Hospital
Modality: Small Molecules
Administration: Topical

Overview

BIL-1 is a novel iodinated boron-dipyrromethene (BODIPY or BDP) derivative developed as a photosensitizer for the treatment of onychomycosis (fungal nail infection). It is designed for use in photodynamic therapy (PDT), where the compound is applied topically to the affected nail and subsequently activated by light irradiation. Upon activation, BIL-1 generates reactive oxygen species (ROS), such as singlet oxygen, which exert a potent antifungal effect by damaging fungal cell membranes and organelles. The drug is currently being evaluated in clinical trials by the Shanghai Skin Disease Hospital and Tongji University School of Medicine to assess its safety and efficacy as a localized treatment for fungal infections.

Other names: iodinated BDP photosensitizer

Targets

^1O2 (Singlet oxygen)

Beyond the preview

Go deeper on BIL-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIL-1.

Explore the full profile